Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2018 16:30 ET | Source: Biogen Inc.

Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018

TOKYO and CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq:BIIB) (Headquarters: Cambridge, Massachusetts,...
July 25, 2018 10:30 ET | Source: Biogen Inc.

Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018

TOKYO and CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq:BIIB) (Headquarters: Cambridge, Massachusetts,...
July 20, 2018 08:39 ET | Source: Biogen Inc.

Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018

CAMBRIDGE, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing a Q&A session related to its Alzheimer’s disease investigational...
July 18, 2018 07:30 ET | Source: Biogen Inc.

Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)

Ongoing Alzheimer’s disease research programs target possible causes of the disease through multiple modalitiesData to be presented from Alzheimer’s disease clinical development portfolio including...
July 05, 2018 19:30 ET | Source: Biogen Inc.

Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months

The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer’s disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta...
June 28, 2018 16:06 ET | Source: Biogen Inc.

Biogen Exercises Option to Increase Ownership in Samsung Bioepis

Biogen will pay Samsung BioLogics approximately $700 million to increase its ownership in Samsung Bioepis to approximately 49.9%Transaction expected to close in the second half of 2018 CAMBRIDGE,...
June 25, 2018 16:01 ET | Source: Biogen Inc.

Biogen to Report Second Quarter 2018 Financial Results on July 24, 2018

CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq:BIIB) today announced it will report second quarter 2018 financial results on Tuesday, July 24, 2018, before the financial...
June 19, 2018 16:01 ET | Source: Biogen Inc.

Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018

CAMBRIDGE, Mass., June 19, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing an overview of its efforts targeting acute ischemic stroke on Thursday,...
June 18, 2018 16:30 ET | Source: Biogen Inc.

Biogen Foundation Selects Grantees to Receive $10 Million Investment for STEM Education

CAMBRIDGE, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- The Biogen Foundation today announced the six nonprofits that will share a previously-announced four-year, $10 million grant to drive the...
June 13, 2018 07:30 ET | Source: Biogen Inc.

Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference

Research includes clinical trial data across broad SMA patient populations, expanding scientific understanding of SMA and SPINRAZA® (nusinersen) Study presented examines neurofilament (pNF-H) as a...